Medmen Enterprises Inc banner
M

Medmen Enterprises Inc
CNSX:MMEN

Watchlist Manager
Medmen Enterprises Inc
CNSX:MMEN
Watchlist
Price: 0.015 CAD Market Closed
Market Cap: CA$20.7m

Relative Value

There is not enough data to reliably calculate the relative value of MMEN.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

MMEN Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Multiples Across Competitors

MMEN Competitors Multiples
Medmen Enterprises Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Medmen Enterprises Inc
CNSX:MMEN
21.6m CAD 0.1 -0.1 -1.8 -0.9
US
Eli Lilly and Co
NYSE:LLY
964.4B USD 14.8 46.7 31.5 33.5
US
Johnson & Johnson
NYSE:JNJ
572.6B USD 6.1 21.4 14.9 18.2
CH
Roche Holding AG
SIX:ROG
284.4B CHF 4.7 30.4 12.8 15
US
Merck & Co Inc
NYSE:MRK
297.7B USD 4.6 16.3 10.2 11.9
UK
AstraZeneca PLC
LSE:AZN
217.3B GBP 5.2 31.9 15.2 22.3
CH
Novartis AG
SIX:NOVN
228.9B CHF 5.2 21 13 16.7
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 333.1 835.4
DK
Novo Nordisk A/S
CSE:NOVO B
1.2T DKK 4 12.2 8.9 10.5
US
Pfizer Inc
NYSE:PFE
151.1B USD 2.4 19.4 7.3 9.7
US
Bristol-Myers Squibb Co
NYSE:BMY
120.9B USD 2.5 20 7.1 9.3
P/E Multiple
Earnings Growth PEG
US
M
Medmen Enterprises Inc
CNSX:MMEN
Average P/E: 24.4
Negative Multiple: -0.1
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
46.7
28%
1.7
US
Johnson & Johnson
NYSE:JNJ
21.4
6%
3.6
CH
Roche Holding AG
SIX:ROG
30.4
29%
1
US
Merck & Co Inc
NYSE:MRK
16.3
14%
1.2
UK
AstraZeneca PLC
LSE:AZN
31.9
38%
0.8
CH
Novartis AG
SIX:NOVN
21
15%
1.4
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
12.2
7%
1.7
US
Pfizer Inc
NYSE:PFE
19.4
26%
0.7
US
Bristol-Myers Squibb Co
NYSE:BMY
20
N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
M
Medmen Enterprises Inc
CNSX:MMEN
Average EV/EBITDA: 45.4
Negative Multiple: -1.8
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
31.5
18%
1.8
US
Johnson & Johnson
NYSE:JNJ
14.9
2%
7.4
CH
Roche Holding AG
SIX:ROG
12.8
5%
2.6
US
Merck & Co Inc
NYSE:MRK
10.2
7%
1.5
UK
AstraZeneca PLC
LSE:AZN
15.2
10%
1.5
CH
Novartis AG
SIX:NOVN
13
9%
1.4
IE
E
Endo International PLC
LSE:0Y5F
333.1
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
8.9
7%
1.3
US
Pfizer Inc
NYSE:PFE
7.3
-4%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
7.1
-9%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
M
Medmen Enterprises Inc
CNSX:MMEN
Average EV/EBIT: 98.2
Negative Multiple: -0.9
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
33.5
17%
2
US
Johnson & Johnson
NYSE:JNJ
18.2
6%
3
CH
Roche Holding AG
SIX:ROG
15
6%
2.5
US
Merck & Co Inc
NYSE:MRK
11.9
6%
2
UK
AstraZeneca PLC
LSE:AZN
22.3
23%
1
CH
Novartis AG
SIX:NOVN
16.7
12%
1.4
IE
E
Endo International PLC
LSE:0Y5F
835.4
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
10.5
8%
1.3
US
Pfizer Inc
NYSE:PFE
9.7
-1%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
9.3
10%
0.9